Dr. Verstovsek is a hematologist-oncologist at MD Anderson and the United Energy Resources, Inc., Professor of Medicine. Dr. Verstovsek is a world-renowned expert in myeloproliferative neoplasms (MPN) and the founder/director of the world’s largest MPN Clinical Research Center. Dr. Verstovsek has received international praise for his role in the development of ground-breaking MPN therapies. He oversaw more than 60 early/advanced phase clinical trials of innovative MPN medications, including ruxolitinib, the only FDA-approved prescription for myelofibrosis (MF) until 2019, and polycythemia vera’s second-line treatment. In this video Dr. Verstovsek discuses the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis.
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported the most recent findings from the MANIFEST study, an open-label, Phase 2 clinical trial of pelabresib, an experimental BET inhibitor, in patients with myelofibrosis, a rare bone marrow malignancy with few therapeutic options. These recent findings, which included more patients and a longer follow-up period than previously reported data, point to pelabresib’s potential as a treatment for myelofibrosis. These findings were presented in poster and oral sessions at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021), which took place in Atlanta, Georgia, from December 11 to 14, 2021, as well as online.